MediWound (NASDAQ:MDWD) Now Covered by Analysts at Craig Hallum

Investment analysts at Craig Hallum started coverage on shares of MediWound (NASDAQ:MDWD) in a report issued on Friday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $39.00 price target on the biopharmaceutical company’s stock. Craig Hallum’s price target would indicate a potential upside of 140.30% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of MediWound in a research report on Friday, January 10th.

MediWound Trading Up 1.6 %

NASDAQ:MDWD opened at $16.23 on Friday. The business’s 50-day moving average is $18.18 and its 200 day moving average is $17.72. MediWound has a 12 month low of $12.78 and a 12 month high of $24.00. The company has a market capitalization of $175.06 million, a P/E ratio of -5.60 and a beta of 0.81.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the previous year, the company posted ($0.24) EPS. On average, research analysts forecast that MediWound will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On MediWound

A number of large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its position in shares of MediWound by 38.0% during the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 2,178 shares during the last quarter. Northern Trust Corp increased its position in shares of MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after purchasing an additional 70,367 shares in the last quarter. MGO One Seven LLC acquired a new position in MediWound in the 4th quarter valued at $216,000. Barclays PLC lifted its holdings in MediWound by 11.2% in the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 1,249 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,162 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.